Posted by Michael Wonder on 27 Apr 2025
Acoramidis approved to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy
25 April 2025 - The MHRA has approved the medicine acoramidis (Beyonttra) to treat adult patients with cardiomyopathy caused by variant or wild-type transthyretin amyloidosis (ATTR-CM).
Acoramidis has been approved via a fast-track approval process for medicines, known as the International Recognition Procedure, following approval by the EMA earlier this year.
